- HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
- HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
- HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
- HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
- HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
- HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- HilleVax to Present at Upcoming Investor Conferences
- HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
- HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
More ▼
Key statistics
On Friday, Hillevax Inc (HLVX:NSQ) closed at 14.06, 41.45% above the 52 week low of 9.94 set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.06 |
---|---|
High | 14.22 |
Low | 13.26 |
Bid | 5.63 |
Offer | 22.49 |
Previous close | 14.10 |
Average volume | 231.58k |
---|---|
Shares outstanding | 49.72m |
Free float | 40.37m |
P/E (TTM) | -- |
Market cap | 699.08m USD |
EPS (TTM) | -3.29 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼